Clinical trial
Baroreflex Activation Therapy for Heart Failure
NCT02627196 · CVRx, Inc., Industry · Unknown status
Key facts
| NCT number | NCT02627196 |
|---|---|
| Title | Baroreflex Activation Therapy for Heart Failure |
| Official title | Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure |
| Acronym | BeAT-HF |
| Lead sponsor | CVRx, Inc., Industry |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Heart Failure |
| Intervention type | Device, Drug |
| Interventions | BAROSTIM NEO® System, Medical Management |
| Enrollment | 1,200 |
| Start date | Apr 19, 2016 |
| Primary completion | Dec 1, 2023 |
| Completion | Dec 1, 2023 |
| First posted | Dec 10, 2015 |
| Last update posted | Jan 23, 2023 |
| Countries | United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: